You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

Investigational Drug Information for Taselisib


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Taselisib?

Taselisib is an investigational drug.

There have been 10 clinical trials for Taselisib. The most recent clinical trial was a Phase 3 trial, which was initiated on April 9th 2015.

The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Genentech, Inc., and Southwest Oncology Group.

There are one hundred and seventeen US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Taselisib
TitleSponsorPhase
Trial of Taselisib in OvergrowthCentre Hospitalier Universitaire DijonPhase 1/Phase 2
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)National Cancer Institute (NCI)Phase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2

See all Taselisib clinical trials

Clinical Trial Summary for Taselisib

Top disease conditions for Taselisib
Top clinical trial sponsors for Taselisib

See all Taselisib clinical trials

US Patents for Taselisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Taselisib ⤷  Try a Trial Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Compounds and combinations for the treatment of HIV Gilead Sciences, Inc. (Foster City, CA) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Tricyclic PI3K inhibitor compounds and methods of use Genentech, Inc. (South San Francisco, CA) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Try a Trial
Taselisib ⤷  Try a Trial Benzoxazepin oxazolidinone compounds and methods of use Genentech, Inc. (South San Francisco, CA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Taselisib

Drugname Country Document Number Estimated Expiration Related US Patent
Taselisib Argentina AR107432 2036-01-11 ⤷  Try a Trial
Taselisib Australia AU2017207268 2036-01-11 ⤷  Try a Trial
Taselisib Australia AU2019203280 2036-01-11 ⤷  Try a Trial
Taselisib Australia AU2021201018 2036-01-11 ⤷  Try a Trial
Taselisib Brazil BR112018014015 2036-01-11 ⤷  Try a Trial
Taselisib Canada CA3010509 2036-01-11 ⤷  Try a Trial
Taselisib China CN108473471 2036-01-11 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.